MTOR and neoplasm: To evaluate PI3K/Akt/mTOR pathway activation in the regression of C4-HD tumors, we used the PI3K inhibitor WORT alone or in combination with MFP for 48 h, finding that WORT interfered with MFP-induced tumor reduction and tissue remodeling (Figure 4A).